Is the SSRI vilazodone effective for treating generalized anxiety disorder? To comprehensively evaluate the effect of vilazodone across the range of anxiety symptoms associated with the disorder, Khan and colleagues conducted post hoc analyses on pooled data from 3 vilazodone trials in generalized anxiety disorder.
Vilazodone shows many differences from the 4 already-approved medications for generalized social anxiety, but how safe is it? This trial tests the safety, efficacy and tolerability of the drug over the course of a 12-week treatment.
Social anxiety disorder is prevalent in patients with schizophrenia. Is it a component of negative symptoms or something distinct? Review results from a study that explored this question as well as predictors that are related to increased social fear in schizophrenia.Â
Premature ejaculation is one of the most common forms of male sexual dysfunction. Recent clinical and genetic evidence suggests that it can be classified into 4 subtypes, which may have distinct clinical profiles. Psychological factors, such as anxiety, may play a specific role in the acquired subtype. The objective of this study was to assess the association between psychological factors, particularly anxiety and marital disharmony, and the various subtypes of premature ejaculation.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT